Sotirios Tsimikas Selected Research

ISIS 304801

1/2021	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
1/2019	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
4/2016	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sotirios Tsimikas Research Topics

Disease

68	Atherosclerosis 01/2022 - 01/2002
63	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 04/2006
26	Inflammation (Inflammations) 01/2021 - 07/2006
25	Coronary Artery Disease (Coronary Atherosclerosis) 12/2021 - 07/2005
24	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 02/2014
23	Myocardial Infarction 01/2021 - 12/2006
18	Atherosclerotic Plaque (Atheroma) 01/2022 - 11/2002
16	Thrombosis (Thrombus) 12/2021 - 06/2002
16	Stroke (Strokes) 01/2021 - 11/2005
11	Acute Coronary Syndrome 11/2020 - 02/2003
10	Coronary Disease (Coronary Heart Disease) 01/2022 - 07/2006
10	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 12/2020 - 05/2006
9	Hypercholesterolemia 01/2019 - 07/2005
8	Rupture 01/2021 - 01/2002
6	Hypertriglyceridemia 01/2022 - 09/2011
6	Peripheral Arterial Disease 01/2021 - 10/2007
5	Ischemic Stroke 01/2021 - 11/2005
5	Pathologic Constriction (Stenosis) 05/2014 - 01/2004
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2011 - 04/2006
4	Unstable Angina 01/2020 - 02/2012
4	Aortic Valve Disease 01/2020 - 01/2017
3	COVID-19 01/2022 - 01/2020
3	Obesity 03/2021 - 09/2011
3	Osteoporosis 01/2021 - 01/2018
3	Injection Site Reaction 01/2021 - 11/2016
3	Type 2 Diabetes Mellitus (MODY) 10/2020 - 01/2014
3	Necrosis 10/2019 - 11/2010
3	Infarction (Infarctions) 01/2019 - 06/2006
3	Neoplasms (Cancer) 11/2018 - 06/2012
3	Diabetes Mellitus 03/2018 - 09/2008
3	Transient Ischemic Attack 03/2018 - 08/2007
3	Stable Angina 05/2016 - 11/2005
2	Cytokine Release Syndrome 01/2022 - 01/2020
2	Transthyretin-Related Hereditary Amyloidosis 06/2021 - 01/2021
2	Hypertension (High Blood Pressure) 06/2021 - 01/2007
2	Polyneuropathies (Polyneuropathy) 06/2021 - 01/2021
2	Amyloidosis 01/2021 - 10/2020

Drug/Important Bio-Agent (IBA)

72	Lipoprotein(a)IBA 01/2022 - 09/2004
48	Phospholipids (Phosphatides)FDA LinkGeneric 01/2022 - 09/2004
47	oxidized low density lipoproteinIBA 01/2021 - 01/2002
43	1-penicillamyl-Leu(2)- oxytocinIBA 01/2022 - 09/2004
37	Apolipoproteins B (ApoB)IBA 01/2022 - 06/2006
35	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
32	Lipoproteins (Lipoprotein)IBA 01/2022 - 07/2005
25	Apolipoprotein B-100 (Apo B 100)IBA 01/2022 - 09/2004
25	EpitopesIBA 01/2019 - 07/2008
24	LipidsIBA 01/2022 - 01/2002
18	CholesterolIBA 12/2020 - 06/2002
16	AntibodiesIBA 01/2021 - 01/2002
16	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2020 - 06/2002
15	ApolipoproteinsIBA 12/2018 - 06/2006
14	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 12/2004
13	Malondialdehyde (Propanedial)IBA 10/2019 - 12/2004
12	Immunoglobulin M (IgM)IBA 10/2019 - 06/2006
11	LDL CholesterolIBA 01/2021 - 04/2006
11	Apolipoproteins E (ApoE)IBA 10/2019 - 09/2006
10	Triglycerides (Triacylglycerol)IBA 01/2022 - 09/2011
10	Apolipoproteins AIBA 10/2020 - 04/2005
9	AutoantibodiesIBA 01/2018 - 01/2006
8	Atorvastatin (Lipitor)FDA Link 01/2017 - 09/2004
8	LDL Receptors (LDL Receptor)IBA 02/2016 - 03/2003
7	Apolipoprotein C-IIIIBA 01/2022 - 10/2015
7	Antisense OligonucleotidesIBA 01/2022 - 05/2014
7	Pharmaceutical PreparationsIBA 06/2021 - 01/2002
7	AntigensIBA 07/2015 - 04/2009
6	Proteins (Proteins, Gene)FDA Link 03/2021 - 12/2006
6	Antigen-Antibody Complex (Immune Complex)IBA 01/2017 - 09/2004
6	Immunoglobulin G (IgG)IBA 01/2017 - 06/2006
6	1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)IBA 08/2012 - 12/2006
5	Proprotein Convertase 9IBA 11/2020 - 05/2014
5	Apoprotein(a) (Apolipoprotein (a))IBA 10/2020 - 04/2009
5	omega-Chloroacetophenone (Mace)IBA 01/2020 - 04/2015
5	Biological ProductsIBA 01/2017 - 06/2006
4	PlasminogenIBA 01/2022 - 04/2012
4	C-Reactive ProteinIBA 01/2022 - 04/2006
4	EnzymesIBA 11/2018 - 12/2006
4	AntioxidantsIBA 01/2017 - 01/2009
4	Phospholipases (Phospholipase)IBA 02/2014 - 02/2012
3	Messenger RNA (mRNA)IBA 01/2022 - 04/2016
3	Prealbumin (Transthyretin)IBA 06/2021 - 10/2020
3	ISIS 304801IBA 01/2021 - 04/2016
3	alirocumabIBA 11/2020 - 01/2020
3	Glucose (Dextrose)FDA LinkGeneric 10/2020 - 04/2016
3	Single-Chain AntibodiesIBA 01/2019 - 10/2011
3	Rosuvastatin Calcium (Crestor)FDA Link 12/2018 - 09/2015
3	HDL CholesterolIBA 10/2018 - 01/2016
3	HDL LipoproteinsIBA 02/2017 - 09/2011
3	Secretory Phospholipases A2IBA 11/2013 - 02/2012
3	Immunoglobulins (Immunoglobulin)IBA 01/2013 - 06/2006
3	Matrix Metalloproteinases (MMPs)IBA 06/2012 - 08/2008
3	Pravastatin (Pravachol)FDA LinkGeneric 01/2011 - 05/2006
2	InterleukinsIBA 01/2022 - 05/2014
2	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2020
2	LigandsIBA 06/2021 - 01/2021
2	Estrogens (Estrogen)FDA Link 01/2021 - 09/2009

Therapy/Procedure

28	Therapeutics 12/2021 - 01/2007
7	Percutaneous Coronary Intervention 05/2016 - 11/2005
6	Stents 01/2015 - 01/2004
4	Blood Component Removal (Apheresis) 01/2019 - 08/2012
2	Injections 01/2021 - 11/2016